Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-01
2005-11-01
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S408000, C514S424000, C514S091000, C514S336000
Reexamination Certificate
active
06960612
ABSTRACT:
Methods for prevention or treatment of pruritus are provided. The methods comprise administering to a patient an effective amount of a kappa opioid receptor agonist compound. The involved kappa opioid receptor agonist compounds are of the type represented by the following formula IIIwherein R1, R2, Ar, X7, and n are as defied in the specification.
REFERENCES:
patent: 4065573 (1977-12-01), Lednicer
patent: 4098904 (1978-07-01), Szmuszkovicz
patent: 4145435 (1979-03-01), Szmuszkovicz
patent: 4212878 (1980-07-01), Lednicer et al.
patent: 4359476 (1982-11-01), Kaplan et al.
patent: 4360531 (1982-11-01), McMillan et al.
patent: 4438130 (1984-03-01), Kaplan
patent: 4463013 (1984-07-01), Collins et al.
patent: 4466977 (1984-08-01), McMillan et al.
patent: 4663343 (1987-05-01), Horwell et al.
patent: 4855316 (1989-08-01), Horwell et al.
patent: 4906655 (1990-03-01), Horwell et al.
patent: 4929627 (1990-05-01), Pannev
patent: 4943578 (1990-07-01), Naylor et al.
patent: 5114945 (1992-05-01), Hayes et al.
patent: 5116842 (1992-05-01), Naylor et al.
patent: 5232978 (1993-08-01), Gottschlich et al.
patent: 5475019 (1995-12-01), Privette et al.
patent: 5532266 (1996-07-01), Gottschlich et al.
patent: 5610271 (1997-03-01), Dooley et al.
patent: 5646151 (1997-07-01), Kruse et al.
patent: 5688955 (1997-11-01), Kruse et al.
patent: 5744458 (1998-04-01), Kruse et al.
patent: 5760023 (1998-06-01), Farrar et al.
patent: 5763445 (1998-06-01), Kruse et al.
patent: 5804595 (1998-09-01), Portoghese et al.
patent: 5849762 (1998-12-01), Farrar et al.
patent: 5869521 (1999-02-01), Farrar et al.
patent: 5888494 (1999-03-01), Farrar et al.
patent: 5945443 (1999-08-01), Kruse et al.
patent: 5981513 (1999-11-01), Kruse et al.
patent: 6004964 (1999-12-01), Farrar et al.
patent: 6028063 (2000-02-01), Kruse et al.
patent: 6048860 (2000-04-01), Farrar et al.
patent: 6054445 (2000-04-01), Zhang et al.
patent: 6057323 (2000-05-01), Zhang et al.
patent: 6156769 (2000-12-01), Farrar et al.
patent: 6180623 (2001-01-01), Kruse et al.
patent: 6239154 (2001-05-01), Zhang et al.
patent: 6303611 (2001-10-01), Zhang et al.
patent: 0 108 602 (1984-05-01), None
patent: 0 147 085 (1984-12-01), None
patent: 0 207 773 (1986-06-01), None
patent: 0 233 793 (1987-01-01), None
patent: 0 254 545 (1988-01-01), None
patent: 0 260 555 (1988-03-01), None
patent: 0 261 842 (1988-03-01), None
patent: 0 372 466 (1988-06-01), None
patent: 0 33 467 (1989-02-01), None
patent: 0 330 461 (1989-02-01), None
patent: 0 325 406 (1989-07-01), None
patent: 0 330 469 (1989-08-01), None
patent: 0 333 427 (1989-09-01), None
patent: 0 366 327 (1989-10-01), None
patent: 0 343 900 (1989-11-01), None
patent: 0 356 247 (1990-02-01), None
patent: 0 393 696 (1990-04-01), None
patent: 0 374 054 (1990-06-01), None
patent: 0 398 720 (1990-11-01), None
patent: 0 409 489 (1991-01-01), None
patent: 0 483 580 (1991-10-01), None
patent: 0 329 563 (1993-04-01), None
patent: 0 569 802 (1993-11-01), None
patent: 0 577 847 (1994-01-01), None
patent: 0 752 246 (1997-01-01), None
patent: WO 90/07502 (1990-07-01), None
patent: WO 92/20657 (1992-11-01), None
patent: WO 94/18165 (1994-08-01), None
patent: WO 95/03308 (1995-02-01), None
patent: WO 96/06077 (1996-02-01), None
patent: WO 96/06078 (1996-02-01), None
patent: WO 97/20831 (1997-06-01), None
patent: WO 97/32857 (1997-09-01), None
patent: WO 98/23290 (1998-06-01), None
patent: WO 99/03468 (1999-01-01), None
patent: WO 99/03499 (1999-01-01), None
patent: WO 00/14065 (2000-03-01), None
Raynor et al., “Pharmacological Characterization of the Cloned κ-, δ-, and μ-Opioid Receptors,”Molecular Pharmacol., 1994, 45, 330-334.
Wheeler-Aceto et al., “Standardization of the rat paw formalin test for the evaluation of analgesics,”Psychopharmacology, 1991, 104, 35-44.
Ballantyne et al., “Itching After Epidural and Spinal Opiates,”Pain, 1988, 33, 149-160.
Bernhard, J.D., “Itching in the Nineties,”J. Am. Acad. Derm., 1991, 24, 309-310.
Bernstein et al., “Antipruritic Effect of an Opiate Antagonist, Naloxone Hydrochloride,”Journal of Investigative Dermatology, 1982, 78(2), 82-83.
McMahon et al., “Itching for an Explanation,”TINS, 1992, 15(12), 497-501.
Thomas et al., “Microinjection of morphine into the rat medullary dorsal horn produces a dose-dependent increase in facial scratching,”Brain Research, 1995, 695(2), 267-270.
Walter, M., “Neural Mechanisms of Itch Sensation,”IASP Newsletter, Sep./Oct. 1996, 1-10.
Szmuszkovicz et al., “Benzeneacetamide Amines: Structurally Novel Non-mμ Opioids,”Journal of Medicinal Chemistry, 1982, 25(10), 1125-6.
Change, et al., “Kappa opioid receptor selective affinity labels: Electrophilic benzeneaceatamides as kappa-selective opioid antagonist,”J. Med. Chem., 1994, 37, 4490-4498.
Freeman et al, “Naphto and Benzo Analogues of the κ Opioid Agonisttrans-(±)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide,”J. Med. Chem., 1991, 34(6), 1891-1896.
Lawhorn et al., “Epidural morphine with butorphanol for postoperative analgesis after cesarean delivery,”Anesthesia and Analgesia, 1991, 72(1), 53-57.
Magerl, W., “Neural Mechanisms of Itch Sensation,”IASP Newsletter, Sep./Oct. 1996, 1-10.
Rajagopalan, P. et al., “DuP 747: Structure activity relationship study,”Bioorganic&Medicinal Chemistry Letters, 1992, 2(7), 721-726.
Collins, et al., US 4,463,013, Jul. 31, 1984,Chemical Abstracts, Chemical Abstract No. 101:204315; Chemical Abstract Registry No. 92953-42-9.
deCosta, B.R., et al., “Probes for narcotic receptor mediated phenomena as opioid receptor ligands,”J. Med. Chem., 1990, 33(4), 1171-1176,ChemicalAbstracts, Chemical Abstract No. 112:138845; Chemical Abstract Registry Nos. 118243-29-1, 124942-79-6, 125072-90-4.
deCosta, B.R., et al., “Selective and enantiospecific acylation of kappa-opioid receptors by . . . ,”J. Med. Chem., 1989, 32(2), 281-283,ChemicalAbstracts, Chemical Abstract No. 110:75224; Chemical Abstract Registry 118243-29-1.
deCosta, B.R., “Synthesis of an affinity ligand (‘UPHIT’) for in vivo acylation of the κ-opioid receptor,”Elsevier Science Publishers B.V., Jun. 1989, XP-000940483, 249(2), 178-182.
Giardina, G., et al., “Central and peripheral analgesic agents, chemical strategies for limiting brain pentration inkappa-opioid agonists belonging to different chemical classes,”Il Farmaco, 1995, 50(6), 405-418.
Hayward, N.J., et al., “The neuroprotective action of kappa-opioid agonists in the gerbil,”Mol. Neuropharmacol, 1992, 2(3), 221-227,ChemicalAbstracts, Chemical Abstract No. 117:245459; Chemical Abstract Registry No. 87173-94-2.
Kaplan, US 4,438,130 Mar. 20, 1984,Chemical Abstracts, Chemical Abstract No. 99;139741; Chemical Abstract Registry No. 87151-85-7.
Li, J.G., et al., “Comparative studies on the affinities of K-11 and U-50488H for kappa opiate receptor,”Yaoxue Wuebao, 1991, 26(1), 10-14,ChemicalAbstracts, Chemical Abstract No. 114:199538; Chemical Abstract Registry No. 106709-52-8.
Scopes, D.I.C., “Selective non-peptide kappa opioid receptor agonists,”Exp. Opin. Invest. Drugs, 1994, 3(4), 369-376.
Szmuszkovicz, US 4,145,435, Mar. 20, 1979, Chemical Abstract No. 89:146631; Chemical Abstract Registry No. 67198-13-4.
Upjohn Co., EP 162690 A2, Nov. 27, 1985,ChemicalAbstracts, Chemical Abstract No. 107:58832; Chemical Abstract Registry No. 109063-12-9.
Upjohn Co., EP 129991 A1, Jan. 2, 1985,ChemicalAbstracts, Chemical Abstract No. 103:160382; Chemical Abstract Registry No. 67198-17-8.
Upjohn Co., EP 126612 A1, Nov. 28, 1984,ChemicalAbstracts, Chemical Abstract No. 102:184969, Chemical Abstract Registry Nos. 95458-07-4, 95585-69-6.
Upjohn Co., EP 108601 A1,Chemical Abstracts, Chemical Abstract No. 102:24297, Chemical Abstract Registry No. 91873-43-7.
Weerawarna, S.A., et al., “Isothiocyanate-substituted κ-se
Chang An-Chih
DeHaven-Hudkins Diane L.
Farrar John J.
Gaul Forrest
Kruse Lawrence I.
Adolor Corporation
Wang Shengjun
Woodcock & Washburn LLP
LandOfFree
Kappa agonist compounds, pharmaceutical formulations and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kappa agonist compounds, pharmaceutical formulations and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kappa agonist compounds, pharmaceutical formulations and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3499903